Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry AndréKai-Keen ShiuTae Won KimBenny Vittrup JensenLars Henrik JensenCornelis PuntDenis SmithRocio Garcia-CarboneroManuel BenavidesPeter GibbsChristelle de la FouchardiereFernando RiveraElena ElezJohanna BendellDung T LeTakayuki YoshinoEric Van CutsemPing YangMohammed Z H FarooquiPatricia MarinelloLuis A Diaznull nullPublished in: The New England journal of medicine (2020)
Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.).